{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:10:51Z","timestamp":1790259051331,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T00:00:00Z","timestamp":1581120000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T00:00:00Z","timestamp":1581120000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002784","name":"Canada Excellence Research Chairs, Government of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background and aims<\/jats:title>\n                <jats:p>Sodium\u2013glucose linked cotransporter-2 (SGLT2) inhibitors reduce the likelihood of hospitalization for heart failure and cardiovascular death in both diabetic and non-diabetic individuals with reduced ejection fraction heart failure. Because SGLT2 inhibitors lead to volume contraction with reductions in both preload and afterload, these load-dependent factors are thought to be major contributors to the cardioprotective effects of the drug class. Beyond these effects, we hypothesized that SGLT2 inhibitors may also improve intrinsic cardiac function, independent of loading conditions.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Pressure\u2013volume (P\u2013V) relationship analysis was used to elucidate changes in intrinsic cardiac function, independent of alterations in loading conditions in animals with experimental myocardial infarction, a well-established model of HFrEF. Ten-week old, non-diabetic Fischer F344 rats underwent ligation of the left anterior descending (LAD) coronary artery to induce myocardial infarction (MI) of the left ventricle (LV). Following confirmation of infarct size with echocardiography 1-week post MI, animals were randomized to receive vehicle, or the SGLT2 inhibitor, empagliflozin. Cardiac function was assessed by conductance catheterization just prior to termination 6\u00a0weeks later.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The circumferential extent of MI in animals that were subsequently randomized to vehicle or empagliflozin groups was similar. Empagliflozin did not affect fractional shortening (FS) as assessed by echocardiography. In contrast, load-insensitive measures of cardiac function were substantially improved with empagliflozin. Load-independent measures of cardiac contractility, preload recruitable stroke work (PRSW) and end-systolic pressure volume relationship (ESPVR) were higher in rats that had received empagliflozin. Consistent with enhanced cardiac performance in the heart failure setting, systolic blood pressure (SBP) was higher in rats that had received empagliflozin despite its diuretic effects. A trend to improved diastolic function, as evidenced by reduction in left ventricular end-diastolic pressure (LVEDP) was also seen with empagliflozin. MI animals treated with vehicle demonstrated myocyte hypertrophy, interstitial fibrosis and evidence for changes in key calcium handling proteins (all p\u2009&lt;\u20090.05) that were not affected by empagliflozin therapy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Empagliflozin therapy improves cardiac function independent of loading conditions. These findings suggest that its salutary effects are, at least in part, due to actions beyond a direct effect of reduced preload and afterload.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-020-0994-y","type":"journal-article","created":{"date-parts":[[2020,2,8]],"date-time":"2020-02-08T07:02:55Z","timestamp":1581145375000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1031-3137","authenticated-orcid":false,"given":"Kim A.","family":"Connelly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Desjardins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Nghiem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Visram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri N.","family":"Batchu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verra G.","family":"Yerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Golam","family":"Kabir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerri","family":"Thai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Advani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,8]]},"reference":[{"key":"994_CR1","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1056\/NEJMra072139","volume":"358","author":"JA Hill","year":"2008","unstructured":"Hill JA, Olson EN. Cardiac plasticity. N Engl J Med. 2008;358:1370\u201380.","journal-title":"N Engl J Med"},{"key":"994_CR2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1611925","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017. https:\/\/doi.org\/10.1056\/NEJMoa1611925.","journal-title":"N Engl J Med."},{"key":"994_CR3","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"994_CR4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812389","author":"SD Wiviott","year":"2018","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2018. https:\/\/doi.org\/10.1056\/NEJMoa1812389.","journal-title":"N Engl J Med."},{"key":"994_CR5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med."},{"key":"994_CR6","doi-asserted-by":"publisher","first-page":"H1699","DOI":"10.1152\/ajpheart.00577.2005","volume":"290","author":"KA Connelly","year":"2006","unstructured":"Connelly KA, Prior DL, Kelly DJ, Feneley MP, Krum H, Gilbert RE. Load-sensitive measures may overestimate global systolic function in the presence of left ventricular hypertrophy: a comparison with load-insensitive measures. Am J Physiol Heart Circ Physiol. 2006;290:H1699\u2013705.","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"994_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.cardiores.2007.06.022","volume":"76","author":"KA Connelly","year":"2007","unstructured":"Connelly KA, Kelly DJ, Zhang Y, Prior DL, Martin J, Cox AJ, et al. Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat. Cardiovasc Res. 2007;76:280\u201391.","journal-title":"Cardiovasc Res"},{"key":"994_CR8","doi-asserted-by":"publisher","first-page":"H501","DOI":"10.1152\/ajpheart.00138.2005","volume":"289","author":"D Burkhoff","year":"2005","unstructured":"Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol Heart Circ Physiol. 2005;289:H501\u201312.","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"994_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1111\/1755-5922.12005","volume":"31","author":"KA Connelly","year":"2013","unstructured":"Connelly KA, Zhang Y, Advani A, Advani SL, Thai K, Yuen DA, et al. DPP-4 inhibition attenuates cardiac dysfunction and adverse remodeling following myocardial infarction in rats with experimental diabetes. Cardiovasc Ther. 2013;31:259\u201367.","journal-title":"Cardiovasc Ther"},{"key":"994_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1161\/CIRCHEARTFAILURE.108.765750","volume":"2","author":"KA Connelly","year":"2009","unstructured":"Connelly KA, Kelly DJ, Zhang Y, Prior DL, Advani A, Cox AJ, et al. Inhibition of protein kinase C-beta by ruboxistaurin preserves cardiac function and reduces extracellular matrix production in diabetic cardiomyopathy. Circ Heart Fail. 2009;2:129\u201337.","journal-title":"Circ Heart Fail"},{"key":"994_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jacbts.2018.11.010","volume":"4","author":"KA Connelly","year":"2019","unstructured":"Connelly KA, Zhang Y, Visram A, Advani A, Batchu SN, Desjardins J-F, et al. Empagliflozin improves diastolic function in a nondiabetic rodent model\u00a0of heart failure with preserved ejection fraction. JACC Basic Transl Sci. 2019;4:27\u201337.","journal-title":"JACC Basic Transl Sci"},{"key":"994_CR12","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s12933-018-0741-9","volume":"17","author":"KA Connelly","year":"2018","unstructured":"Connelly KA, Zhang Y, Desjardins JF, Thai K, Gilbert RE. Dual inhibition of sodium\u2013glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction. Cardiovasc Diabetol. 2018;17:99.","journal-title":"Cardiovasc Diabetol"},{"key":"994_CR13","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1161\/CIRCULATIONAHA.105.587519","volume":"113","author":"L Van Heerebeek","year":"2006","unstructured":"Van Heerebeek L. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113:1966\u201373.","journal-title":"Circulation"},{"key":"994_CR14","first-page":"1","volume":"61","author":"S Verma","year":"2018","unstructured":"Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:1\u201310.","journal-title":"Diabetologia"},{"key":"994_CR15","first-page":"2117","volume":"373","author":"S Verma","year":"2019","unstructured":"Verma S, Mazer CD, Yan AT, Mason T, Garg V, Teoh H, et al. Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial. Circulation. 2019;373:2117\u201312.","journal-title":"Circulation."},{"key":"994_CR16","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1111\/imj.14260","volume":"49","author":"ND Cohen","year":"2019","unstructured":"Cohen ND, Gutman SJ, Briganti EM, Taylor AJ. Effects of empagliflozin treatment on cardiac function and structure in patients with type 2 diabetes: a cardiac magnetic resonance study. Intern Med J. 2019;49:1006\u201310.","journal-title":"Intern Med J."},{"key":"994_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1161\/CIRCHEARTFAILURE.112.000074","volume":"6","author":"X Li","year":"2013","unstructured":"Li X, Qi Y, Li Y, Zhang S, Guo S, Chu S, et al. Impact of mineralocorticoid receptor antagonists on changes in cardiac structure and function of left ventricular dysfunction: a meta-analysis of randomized controlled trials. Circ Heart Fail. 2013;6:156\u201365.","journal-title":"Circ Heart Fail"},{"key":"994_CR18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(88)90347-9","volume":"1","author":"N Sharpe","year":"1988","unstructured":"Sharpe N, Murphy J, Smith H, Hannan S. Treatment of patients with symptomless left ventricular dysfunction after myocardial infarction. Lancet. 1988;1:255\u20139.","journal-title":"Lancet"},{"key":"994_CR19","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1002\/ehf2.12336","volume":"5","author":"J Mustroph","year":"2018","unstructured":"Mustroph J, Wagemann O, L\u00fccht CM, Trum M, Hammer KP, Sag CM, et al. Empagliflozin reduces Ca\/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes. ESC Heart Fail. 2018;5:642\u20138.","journal-title":"ESC Heart Fail"},{"key":"994_CR20","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.1002\/ejhf.1328","volume":"20","author":"S Pabel","year":"2018","unstructured":"Pabel S, Wagner S, Bollenberg H, Bengel P, Kov\u00e1cs \u00c1, Schach C, et al. Empagliflozin directly improves diastolic function in human heart failure. Eur J Heart Fail. 2018;20:1690\u2013700.","journal-title":"Eur J Heart Fail"},{"key":"994_CR21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s00210-015-1134-1","volume":"388","author":"MC Michel","year":"2015","unstructured":"Michel MC, Mayoux E, Vallon V. A comprehensive review of the pharmacodynamics of the SGLT2 inhibitor empagliflozin in animals and humans. Naunyn-Schmied Arch Pharmacol. 2015;388:801\u201316.","journal-title":"Naunyn-Schmied Arch Pharmacol"},{"key":"994_CR22","doi-asserted-by":"publisher","first-page":"S53","DOI":"10.1016\/j.amjcard.2017.05.011","volume":"120","author":"SV Pham","year":"2017","unstructured":"Pham SV, Chilton RJ. EMPA-REG OUTCOME: the cardiologist\u2019s point of view. Am J Cardiol. 2017;120:S53\u20138.","journal-title":"Am J Cardiol"},{"key":"994_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-019-0889-y","author":"A Yoshii","year":"2019","unstructured":"Yoshii A, Nagoshi T, Kashiwagi Y, Kimura H, Tanaka Y, Oi Y, et al. Cardiac ischemia\u2013reperfusion injury under insulin-resistant conditions: SGLT1 but not SGLT2 plays a compensatory protective role in diet-induced obesity. Cardiovasc Diabetol. 2019. https:\/\/doi.org\/10.1186\/s12933-019-0889-y.","journal-title":"Cardiovasc Diabetol"},{"key":"994_CR24","doi-asserted-by":"publisher","first-page":"H2049","DOI":"10.1152\/ajpheart.00393.2004","volume":"287","author":"EE Morgan","year":"2004","unstructured":"Morgan EE, Faulx MD, McElfresh TA, Kung TA, Zawaneh MS, Stanley WC, et al. Validation of echocardiographic methods for assessing left ventricular dysfunction in rats with myocardial infarction. Am J Physiol Heart Circ Physiol. 2004;287:H2049\u201353.","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"994_CR25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1911303.","journal-title":"N Engl J Med."},{"key":"994_CR26","first-page":"997","volume":"41","author":"GM Felker","year":"2003","unstructured":"Felker GM, Benza RL, Chandler AB, Leimberger JD, Cuffe MS, Califf RM, et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. JAC. 2003;41:997\u20131003.","journal-title":"JAC"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-0994-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12933-020-0994-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-020-0994-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,8]],"date-time":"2021-02-08T21:59:02Z","timestamp":1612821542000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-020-0994-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,8]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["994"],"URL":"https:\/\/doi.org\/10.1186\/s12933-020-0994-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,8]]},"assertion":[{"value":"11 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 January 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal studies were approved by the St Michael\u2019s Hospital Animal Care Committee in accordance with the Guide for the Care and Use of Laboratory Animals (NIH Publication No. 85-23, revised 1996).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed this version of the manuscript and consent to publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"KAC has received research grants to his institution from Astra Zeneca and Boehringer Ingelheim, received support for travel to scientific meeting from Boehringer Ingelheim and honoraria for speaking engagements and ad hoc participation in advisory boards from Astra Zeneca, Boehringer Ingelheim and Janssen. REG has received research grants to his institution from Astra Zeneca and Boehringer Ingelheim, received support for travel to scientific meeting from Astra Zeneca and honoraria for speaking engagements and ad hoc participation in advisory boards from Astra Zeneca, Boehringer Ingelheim and Janssen. A.A. has received research support through his institution from AstraZeneca and Boehringer Ingelheim and KC, REG and AA are listed as inventors on a patent application by Boehringer Ingelheim on the use of DPP-4 inhibitors in heart failure.All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"13"}}